Dr. David Rizzieri, MD

by | Jun 12, 2020

Dr. David Rizzieri, MD

rofessor of Medicine, Member of the Duke Cancer Institute, Duke University School of Medicine

As a translational researcher, I have focused my efforts on developing new therapies for patients with leukemia or lymphoma. I am a member of the Combined International Bone Marrow Transplant Registry Lymphoma Writing Committee and the ALLIANCE (formerly CALGB) Leukemia Core Committee. I serve as chair or co-chair of multiple ALLIANCE lymphoma/ leukemia trials, the most recent being the last 2 national studies for Burkitt’s lymphoma, as well as the recent AML intergroup study. I have led our team’s novel approaches for the care of patients using non-myeloablative allogeneic therapy using haplo-identical, as well as matched donors. This work is currently being extended with post-transplant graft manipulation studies focused on manipulating Natural Killer cell activity. I have also led the first in human studies targeting acute myelogenous leukemia by linking diphtheria to a small molecule targeting the IL-3 receptor (now in phase 3). I serve on various NIH/NHLBI grant review committees and am a member of ASH, ASCO, AACR, ASBMT, ASCI, and the ASH sub-committee on Government Affairs. I oversee the development and conduct of all clinical trials in adults with hematologic malignancies conducted in the Duke Cancer Institute. In recognition of this leadership and success in our clinical research efforts, I was fortunate to receive the NIH ‘Clinical Investigator Team Leadership Award’ in 2010.

  • IMPORTANT DISCLOSURE REGARDING PAID EXPERTS AND MATERIAL NON-PUBLIC INFORMATION:

    JMP has adopted certain policies and procedures to verify that our featured experts can identify “material non-public information” and that they will not divulge any such information during our discussion. Such experts are required, among other things, to certify that they have no other conflict, contractual or otherwise, that would make their presentation contrary to any rule, law or regulation.

    Dr. Shubham Pant has been vetted and approved by JMP’s Research and/or Compliance Department for participation in this JMP Securities Hematology and Oncology Summit 12/7/21.

  • Dr. Shubham Pant, MD

    Associate Professor, Department of Gastrointestinal Medical Oncology and Department of Investigational Cancer Therapeutics University of Texas MD Anderson Cancer Center

    ITherapeutics University of Texas MD Anderson Cancer Center

    Dr. Shubham Pant is an Associate Professor in the Department of Gastrointestinal Medical Oncology with a joint appointment in the Department of Investigational Cancer Therapeutics at the University of Texas MD Anderson Cancer Center. Dr. Pant is a key opinion leader in the fields of Phase 1 (Early drug development) and GI Cancers including pancreatic, biliary, gall bladder and colorectal cancer.

    He has an expertise in Targeted therapy and Immunotherapy and has co-authored numerous peer-review articles and is a Section Editor for the Handbook of Targeted Therapy and Immunotherapy. In addition, he has presented or has been coauthor on more than 100 abstracts in national and international meetings including ASCO, AACR. ESMO, ESMO GI, ASCO GI and the NCI-EORTC-AACR (Triple meeting). He is a collaborator of numerous grants including R01 grant from the National Institute of Health and serves as the Clinical Co-leader on NCI Specialized Programs of Research Excellence (SPORE) project 3. He also serves as a member on the National Cancer Institute, Pancreas Task Force and helped draft the ASCO Metastatic Pancreatic Cancer Guidelines that provides evidence-based recommendations to serve as a guide for physicians. Nationally, he is a member of the Arm Selection Committee of Precision Promise, a Pancreatic Cancer Action Network (PanCan) initiative.

    Dr. Pant completed his fellowship from the James Cancer Hospital/Solove Research Institute at the Ohio State University where he was elected Chief Fellow. He has previously served as the Director of Clinical Trials, Section of Hematology- and as Associate Director of the TSET Phase I Program at the University of Oklahoma. He was recipient of the Mai Eager Anderson Endowed Chair in Cancer Clinical Trials, was featured in “40 under 40” in Oklahoma magazine and has been voted by his peers as “America’s Top Doctors” (Castle Connolly) five years in a row. For his patient care, at OU, he was awarded the Golden Pillar Award for Outstanding Patient Service twice for achieving patient satisfaction scores in the top 90th percentile as measured by the OU Medicine EXCEL initiative.

    Dr. Pant completed his fellowship from the James Cancer Hospital/Solove Research Institute at the Ohio State University where he was elected Chief Fellow. He has previously served as the Director of Clinical Trials, Section of Hematology- and as Associate Director of the TSET Phase I Program at the University of Oklahoma. He was recipient of the Mai Eager Anderson Endowed Chair in Cancer Clinical Trials, was featured in “40 under 40” in Oklahoma magazine and has been voted by his peers as “America’s Top Doctors” (Castle Connolly) five years in a row. For his patient care, at OU, he was awarded the Golden Pillar Award for Outstanding Patient Service twice for achieving patient satisfaction scores in the top 90th percentile as measured by the OU Medicine EXCEL initiative.

  • Dr. Brian Brown

    Director (Interim)

    Icahn Genomics Institute

    Dr. Brian Brown is the Acting Director of the Icahn Genomics Institute and Associate Director of the Precision Immunology Institute (PrIISM) at the Mount Sinai School of Medicine in New York City. He is also a Professor in the Department of Genetics and Genomic Sciences and Tisch Cancer Institute. He is an expert immunologist and biotechnologist, with several licensed patents for gene therapy and genetic engineering, including inventing a powerful gene targeting technology that is now being used in different therapies undergoing human clinical trials for glioblastoma, multiple myeloma, and breast cancer. He is on the scientific advisory board of Oncorus and he consults for a wide range of companies. Dr. Brown has been awarded two of the NIH’s most prestigious awards, the New Innovator Award and the NIH Director’s Transformative Research Award. Dr. Brown’s research spans a wide range of areas that include cancer immunology and functional genomics. His lab is also working on several new therapeutic approaches for cancer and inflammatory disease using unique gene and cell engineering approaches.

  • Richard T Silver, MD

    Professor Emeritus of Medicine

    Weill Cornell Medical College

    Dr. Silver is Professor Emeritus of Medicine at Weill Cornell Medical College and an attending physician at The New York Presbyterian Hospital. He is also the Emeritus Director, Richard T Silver Myeloproliferative Neoplasms Center, Weill Cornell Medical College. He received his AB and his MD degree from Cornell University and completed an internship and residency (hematology/oncology) at New York Hospital-Cornell Medical Center. He also was a Clinical Associate at the National Cancer Institute, NIH. As a Visiting Fulbright Professor at the University of Bahia, Salvador, Brazil, Dr. Silver helped establish a residency program, supported by the Rockefeller Foundation. His research included the study of blood groups of the primitive Indians of the Upper Xingu River region, which led to his discovery of the third allele in the Kidd blood subgroup, among other findings.

    Dr. Silver is internationally recognized as one of the pioneers in clinical cancer chemotherapy and clinical and translational investigations in the myeloproliferative neoplasms (MPNs) and chronic myeloid leukemia. He is particularly known for the broad clinical application of the interferons for treating these diseases and is widely credited with developing and popularizing the use of the bone marrow biopsy technique used worldwide for the diagnosis of hematologic disorders.

    He is a prolific author and lecturer at many national and international meetings and has held many distinguished visiting professorships. He has co-chaired 12 international congresses on MPNs. His many honors include the Career Achievement Award for Clinical Research in Hematology from Celgene Corporation; Gedalio and Sonia Grinberg/Nathaniel Wisch, MD, Endowed Visiting Lectureship Award, Icahn School of Medicine at Mount Sinai; the European Leukemia Net Merit Award; the Levine Cancer Institute/University of North Carolina, Charlotte Outstanding Achievement Award; and Honorary Lifetime Achievement Awards from the Israeli Society of Hematology and Blood Transfusion and the University of Texas MD Anderson Cancer Center. The Richard T Silver Distinguished Professor of Hematology and Oncology and the Richard T Silver MPN Center at Weill Cornell Medical College have been named in recognition of his contributions to the understanding and treatment of MPNs.

  • Dr. Ronald Hoffman, MD

    Albert A. and Vera G. List Professor of Medicine

    Director, Myeloproliferative Disorders Research

    Ronald Hoffman, MD, is the Albert A. and Vera G. List Professor of Medicine, Professor of Medicine (Hematology and Medical Oncology), and Director of the Myeloproliferative Disorders Research Program. He founded this program in 2007 and has developed it into one of the most effective and well respected programs in the world dealing with myeloproliferative disorders. His interest in this group of blood cancers stemmed from his time as a fellow in Hematology at Mount Sinai (1974-1977.), where he worked with numerous Mount Sinai faculty including Drs. Ralph Zalusky, Esmail Zanjani, and Lewis Wasserman. After holding administrative positions at several other institutions, Dr. Hoffman retuned to Mount Sinai in 2007 to work in the laboratory and the clinics in order to focus on translational research in blood cancers. He continues to care for patients with myeloproliferative neoplasms on a daily basis.

    Dr. Hoffman is a leader in stem cell research. His studies of human hematopoietic stem cells and progenitor cells in myeloproliferative neoplasms have led to many therapeutic advances. He has also pioneered a unique method of increasing the number of cord blood stem cells used to treat patients with blood cancers and blood disorders.

    In 2003, Dr. Hoffman founded the Myeloproliferative Neoplasm Research Consortium, a multi-institutional program project grant funded by the National Cancer Institute, which is committed to research in and treatment of myeloproliferative neoplasms. The Consortium involves 12 institutions throughout the United States and Canada and is focused on identifying new therapies for patients with myeloproliferative neoplasms and evaluating their effectiveness in carefully constructed clinical trials

    Dr. Hoffman has served as president of the American Society of Hematology and the International Society for Experimental Hematology.

    Dr. Hoffman is the editor of Hematology: Basic Principles and Practice. He conceptualized and organized this leading textbook of hematology, which is currently entering its eighth edition. He is an author on almost 500 peer-reviewed publications and 130 books/book chapters/reviews. He has also served as the editor of the journal Experimental Hematology.

    Dr. Hoffman has mentored countless post-doctoral fellows and junior faculty, and serves as advisor to the Mentoring Committee for junior faculty at the Icahn School of Medicine at Mount Sinai.

    In 2017 Dr. Hoffman received the prestigious Mentor Award from American Society of Hematology in recognition of his outstanding commitment to the training and career development of early-career hematologists and advancing research and patient care in hematology.

  • Dr. Ellen W. Friedman

    Associate Director Hematology

    Montefiore Medical Center/Albert Einstein College of Medicine

    Dr. Friedman’s passion is the study of the blood (hematology) and ensuring that the next generation of medical practitioners are prepared to analyze blood-related problems and to treat them. Dr. Friedman is the Hematology Fellowship Director of Montefiore Medical Center/Albert Einstein College of Medicine since 2005. She graduated her fellowship in Hematology in 1975 at New York University, specializing in the conditions of red cells, platelets and hematologic malignancies. She has been engaged in diagnosing and treating these conditions while simultaneously teaching medical students, medical residents and fellows in the skills and knowledge required. She trained at New York Hospital/Cornell, Bellevue, New York University and has been an attending in teaching programs in New York City her entire career. She has 46 years’ experience in caring for patients in the Bronx both in the city hospitals and at Montefiore/Albert Einstein College of Medicine.

  • IMPORTANT DISCLOSURE REGARDING PAID EXPERTS AND MATERIAL NON-PUBLIC INFORMATION:

    JMP has adopted certain policies and procedures to verify that our featured experts can identify “material non-public information” and that they will not divulge any such information during our discussion. Such experts are required, among other things, to certify that they have no other conflict, contractual or otherwise, that would make their presentation contrary to any rule, law or regulation.

    The featured speakers has been vetted and approved by JMP’s Research and/or Compliance Department for participation in this discussion.

  • IMPORTANT DISCLOSURE REGARDING PAID EXPERTS AND MATERIAL NON-PUBLIC INFORMATION:

    JMP has adopted certain policies and procedures to verify that our featured experts can identify “material non-public information” and that they will not divulge any such information during our discussion. Such experts are required, among other things, to certify that they have no other conflict, contractual or otherwise, that would make their presentation contrary to any rule, law or regulation.

    The featured speakers has been vetted and approved by JMP’s Research and/or Compliance Department for participation in this discussion.

    • Dr. Silver has a financial interest in Protagonist Therapeutics, Inc (PTGX).
    • Dr. Hoffman is a consultant for Protagonist Therapeutics, Inc (PTGX) and served as an Investigator on PTGX’s clinical trial.

  • Dr. Kami Maddocks, MD

    Professor of Clinical Internal Medicine, Lymphoma Program Director, Division of Hematology, Department of Internal Medicine, The James Cancer Hospital at The Ohio State University

    Dr. Kami Maddocks is an associate professor of clinical internal medicine in the Division of Hematology at The Ohio State University. Her job includes working as a hematologist specializing in treating patients with B-cell malignancies, including non-Hodgkin’s lymphoma (NHL), Hodgkin’s lymphoma (HD) and chronic lymphocytic Leukemia (CLL) and researching new therapies for these hematologic malignancies, largely through evaluating new targeted therapies in clinical trials.

    Dr. Maddocks received her medical degree from the University of South Dakota, followed by an internal medicine internship and residency at Mayo Clinic Rochester, Minnesota. She completed a fellowship in hematology/oncology at The Ohio State University and stayed on to join the hematology team. She has board certification in internal medicine, medical oncology and hematology.

    Dr. Maddocks is an investigator on several clinical trials in lymphoma, most of which are evaluating non-chemotherapeutic approaches to the treatment of lymphoma. She also serves on the Alliance Lymphoma Committee, a multi-institution working group to develop clinical trials in lymphoma that can be done across several institutions.

  • Dr. Eytan Stein, MD

    Assistant Attending Physician, Director, Program for Drug Development in Leukemia, Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center

    Dr. Eytan Stein received his medical degree from Northwestern University in Chicago, where he also completed his internal medicine residency. He then completed his fellowships in medicine at Weill Cornell Medical College, and in medical oncology and hematology at Memorial Sloan Kettering. He is an Assistant Professor on the Leukemia Service at Memorial Sloan Kettering Cancer Center in New York City.

    Dr. Stein holds board certification from the American Board of Internal Medicine, American Board of Clinical Oncology, and the American Board of Hematology. He focuses his practice on the treatment of acute and chronic leukemias, myelodysplastic syndromes, and myeloproliferative neoplasms. His research interests include developing novel, early phase clinical trials of compounds that target the genetic and epigenetic basis of myeloid malignancies.

  • Dr. Nina Shah, MD

    Associate Professor, Department of Medicine, University of California, San Francisco

    Dr. Nina Shah is a hematologist who specializes in the treatment of multiple myeloma, a type of cancer affecting the blood marrow. She treats patients at the Hematology and Blood Marrow and Transplant Clinic.

    Nina received a bachelor’s degree in cognitive neuroscience at Harvard University, followed by a medical degree from New York University School of Medicine. She then completed a residency in internal medicine at Columbia University and a fellowship in hematology/oncology at University of Texas MD Anderson Cancer Center.

    Nina’s areas of professional interest include the intersection of immunology and oncology and helping patients fight multiple myeloma by boosting their immune systems.

    An associate professor at UCSF, Dr. Shah belongs to the American Society of Clinical Oncology, the American Society of Hematology and the American Society for Blood and Marrow Transplantation. She speaks Bengali and Spanish.

  • IMPORTANT DISCLOSURE REGARDING PAID EXPERTS AND MATERIAL NON-PUBLIC INFORMATION:

    JMP has adopted certain policies and procedures to verify that our featured experts can identify “material non-public information” and that they will not divulge any such information during our discussion. Such experts are required, among other things, to certify that they have no other conflict, contractual or otherwise, that would make their presentation contrary to any rule, law or regulation.

    The featured speakers has been vetted and approved by JMP’s Research and/or Compliance Department for participation in this discussion.

     

  • Dr. David Berry, M.D., Ph.D.

    General Partner, Flagship Pioneering

    David Berry is a General Partner at Flagship Pioneering and Founder and CEO of Integral Health. He has founded over 25 companies including Indigo Agriculture, Seres Therapeutics (NASDAQ: MCRB), Eleven Biotherapeutics (NASDAQ: EBIO), T2 Biosystems (NASDAQ: TTOO), Evelo Biosciences (NASDAQ: EVLO), Axcella Health (NASDAQ: AXLA), and Joule Unlimited. David has been broadly recognized as a world-leading innovator: elected as a Young Global Leader by the World Economic Forum, named as Innovator of the Year by Technology Review from amongst its Annual TR35 list, and selected as one of 12 Innovators Reshaping Reality by the U.S. State Department, alongside pioneers such as Tim Berners-Lee. He holds over 200 patents and patent applications. David and his companies have been awarded with over 150 additional awards and honors. David currently serves on the United Nations Sustainable Development Solutions Network (UN SDSN), where he was a Founding Leadership Council Member. David received his MD from Harvard Medical School and his PhD from MIT in Biological Engineering.

  • Dr. Graham Walmsley, M.D., Ph.D.

    General Partner, Logos Capital

    Dr. Walmsley serves as General Partner of Logos Capital. Prior to Logos, Dr. Walmsley was a Principal and Manager of the crossover fund at Versant Ventures where he invested in biotechnology companies across multiple funds totaling over $1.5 billion in AUM. While at Versant, Dr. Walmsley served as a board director, built and launched multiple companies (including BlueRock Therapeutics acquired by Bayer), and was head of business development for Jecure Therapeutics through its acquisition by Roche. Dr. Walmsley currently serves on the board of Akero Therapeutics (NASDAQ: AKRO) and ALX Oncology (private). Dr. Walmsley has authored more than 60 scientific publications and holds an MD and PhD from Stanford University School of Medicine.

  • Brad Loncar

    Chief Executive Officer, Loncar Investments

    Brad Loncar is a biotechnology industry investor and CEO of Loncar Investments, a firm that specializes in the creation of precision biotechnology investment opportunities. He is the creator of two Nasdaq-listed biotechnology focused exchange-traded funds. He is an expert in a wide range of topics including oncology and the biotech industry in China. Brad previously worked in the financial services industry at Franklin Templeton Investments where he was a member of the Management Training Program, and was appointed to serve in a Senior Advisor role at the U.S. Department of the Treasury. He currently writes biotechnology commentary at www.LoncarBlog.com and contributes opinion pieces to Endpoints News.

  • Dr. Shinichiro Fuse, Ph.D.

    Managing Director, MPM Capital

    Dr. Shinichiro (Shin) Fuse is focused on advancing MPM’s investment identification, due diligence and business development activities. Shin is an investment committee member of the UBS Oncology Impact Fund (OIF), an oncology-only crossover fund (both private and public equities) managed by MPM, and supports MPM’s relationship with Astellas. Shin serves on the board of Triplet Therapeutics and Orna Therapeutics, and is a board observer for CODA Biotherapeutics and Repare Therapeutics. He previously served operational roles at portfolio companies as the interim CEO of Orna Therapeutics and interim SVP of Business Development at ElevateBio.

    Prior to joining MPM, he was Director of Business Development at bluebird bio, where he was instrumental in executing and managing key industry and academic partnerships in the fields of cell and gene therapy, cancer immunotherapy and genome editing, including partnerships with Five Prime Therapeutics, National Cancer Institute and the acquisition of Pregenen. Previously, he was at Campbell Alliance (Syneos Health) as a life science strategy consultant, and at PureTech Ventures, where he was a member of the founding team of Vedanta Biosciences. He also serves as a columnist for Nikkei Biotech, the leading biotech journal in Japan.

    Shin received his Ph.D. in Microbiology and Immunology from Dartmouth College, an M.S. in Biomedical Science from the University of Tokyo, and a B.Eng. in Applied Chemistry from Keio University in Japan.

  • Dr. David Rizzieri, MD

    rofessor of Medicine, Member of the Duke Cancer Institute, Duke University School of Medicine

    As a translational researcher, I have focused my efforts on developing new therapies for patients with leukemia or lymphoma. I am a member of the Combined International Bone Marrow Transplant Registry Lymphoma Writing Committee and the ALLIANCE (formerly CALGB) Leukemia Core Committee. I serve as chair or co-chair of multiple ALLIANCE lymphoma/ leukemia trials, the most recent being the last 2 national studies for Burkitt’s lymphoma, as well as the recent AML intergroup study. I have led our team’s novel approaches for the care of patients using non-myeloablative allogeneic therapy using haplo-identical, as well as matched donors. This work is currently being extended with post-transplant graft manipulation studies focused on manipulating Natural Killer cell activity. I have also led the first in human studies targeting acute myelogenous leukemia by linking diphtheria to a small molecule targeting the IL-3 receptor (now in phase 3). I serve on various NIH/NHLBI grant review committees and am a member of ASH, ASCO, AACR, ASBMT, ASCI, and the ASH sub-committee on Government Affairs. I oversee the development and conduct of all clinical trials in adults with hematologic malignancies conducted in the Duke Cancer Institute. In recognition of this leadership and success in our clinical research efforts, I was fortunate to receive the NIH ‘Clinical Investigator Team Leadership Award’ in 2010.

  • Mark Lehmann

    President, JMP Securities

    Mark Lehmann is President of JMP Securities. He is also a member of the executive committee of JMP Group and serves on its board of directors.

    Prior to joining JMP in 2003, Mark served both as the Global Director of Institutional Sales and as the Global Director of Equity Research at Banc of America Securities after working as an institutional salesperson at the firm and its predecessor, Montgomery Securities, for 11 years.

    Mark holds a JD from the New York University School of Law and an undergraduate degree from the University of Illinois. He is also a certified public accountant.

  • Dr. Michael Howard, PhD, DABMP, RSO

    Director of Oncology Services, Chief of Medical Physics, Sarah Cannon Cancer Institute, Parkridge Medical Center, HCA Healthcare

    Dr. Michael Howard has served as Director of Oncology Services for ~14 years, and holds the roles of both Chief of Medical Physics as well as Radiation Safety Officer for the Sarah Cannon Cancer Institute at Parkridge Medical Center in Tennessee. Dr. Howard has practiced medical physics for ~24 years, and additional has held several positions within the American Association of Physicists in Medicine (AAPM). He received his PhD from the University of Tennessee, where he now is a director and adjunct faculty member for the school’s medical Physics Graduate Program.

  • Dr. Randy Hicks, M.D., M.B.A.

    Chief Executive Officer, Regional Medical Imaging

    Dr. Randy Hicks, serves as the co-owner and CEO of RMI, a leading image services provider in mid- and southern Michigan with a central focus on women’s health. Dr. Hicks is a distinguished expert on woman’s imaging for breast cancer, and has co-authored several medical journal articles on the area. He is a graduate of Michigan State University’s College of Human Medicine and completed a residency in diagnostic radiology at Michigan State University affiliated hospitals. Dr. Hicks was board certified by the American Board of Radiology in 1989 and earned an MBA from Michigan State university in 1997.

  • IMPORTANT DISCLOSURE REGARDING PAID EXPERTS AND MATERIAL NON-PUBLIC INFORMATION:

    JMP has adopted certain policies and procedures to verify that our featured experts can identify “material non-public information” and that they will not divulge any such information during our discussion. Such experts are required, among other things, to certify that they have no other conflict, contractual or otherwise, that would make their presentation contrary to any rule, law or regulation.

    The featured speakers have been vetted and approved by JMP’s Research and/or Compliance Department for participation in this discussion.

  • IMPORTANT DISCLOSURE REGARDING PAID EXPERTS AND MATERIAL NON-PUBLIC INFORMATION:

    JMP has adopted certain policies and procedures to verify that our featured experts can identify “material non-public information” and that they will not divulge any such information during our discussion. Such experts are required, among other things, to certify that they have no other conflict, contractual or otherwise, that would make their presentation contrary to any rule, law or regulation.

    The featured speakers have been vetted and approved by JMP’s Research and/or Compliance Department for participation in this discussion.

  • IMPORTANT DISCLOSURE REGARDING PAID EXPERTS AND MATERIAL NON-PUBLIC INFORMATION:

    JMP has adopted certain policies and procedures to verify that our featured experts can identify “material non-public information” and that they will not divulge any such information during our discussion. Such experts are required, among other things, to certify that they have no other conflict, contractual or otherwise, that would make their presentation contrary to any rule, law or regulation.

    The featured speakers have been vetted and approved by JMP’s Research and/or Compliance Department for participation in this discussion.

  • IMPORTANT DISCLOSURE REGARDING PAID EXPERTS AND MATERIAL NON-PUBLIC INFORMATION:

    JMP has adopted certain policies and procedures to verify that our featured experts can identify “material non-public information” and that they will not divulge any such information during our discussion. Such experts are required, among other things, to certify that they have no other conflict, contractual or otherwise, that would make their presentation contrary to any rule, law or regulation.

    The featured speakers have been vetted and approved by JMP’s Research and/or Compliance Department for participation in this discussion.

    • Dr. Jordan Gauthier is a Clinical Investigator of trials of autologous CD19-targeted CAR T cell therapy.

  • Dr. Jordan Gauthier, M.D., M.Sc.

    Assistant Professor, Clinical Research Division, Fred Hutchinson Cancer Research Center

    Jordan Gauthier, MD, MSc, is an Assistant Professor at the Fred Hutchinson Cancer Research Center (FHCRC and the University of Washington in Seattle, WA. Dr. Jordan Gauthier is developing and improving cellular immunotherapies for people with blood cancers like leukemia and lymphoma. These therapies include blood stem cell transplantation and a genetically modified immune cell therapy called chimeric antigen receptor T-cell therapy (or CAR T-cell therapy).

    In addition to designing and conducting clinical trials, Dr. Gauthier builds innovative statistical and machine-learning models to predict patient outcomes on these therapies. Web applications and other new tools he develops will help doctors and patients understand and predict how well cellular therapy will work for them.

    Dr. Gauthier is also a hematologist-oncologist who cares for patients with blood cancers, especially those undergoing transplant or immunotherapy. He was the first physician to be awarded the FHCRC Immunotherapy Integrated Research Center Fellowship.

    An expert in the field of CAR-T cell therapy and hematopoietic cell transplantation (HCT), he has co-authored over 30 publications in the field of immunotherapy and HCT, thirteen of them as first author in high impact factors journals such as Blood, Blood Advances, Bone Marrow Transplantation and Transplantation.

  • IMPORTANT DISCLOSURE REGARDING PAID EXPERTS AND MATERIAL NON-PUBLIC INFORMATION:

    JMP has adopted certain policies and procedures to verify that our featured experts can identify “material non-public information” and that they will not divulge any such information during our discussion. Such experts are required, among other things, to certify that they have no other conflict, contractual or otherwise, that would make their presentation contrary to any rule, law or regulation.

    The featured speakers have been vetted and approved by JMP’s Research and/or Compliance Department for participation in this discussion.

  • Dr. Joleen Hubbard, M.D.

    Associate Professor of Medical Oncology, Mayo Clinic

    Dr. Joleen Hubbard is an Associate Professor of Medical Oncology at Mayo Clinic, Rochester MN. She completed medical school and residency at the University of Minnesota and hematology/oncology fellowship at Mayo Clinic, Rochester MN. Dr. Hubbard specializes in the treatment of gastrointestinal cancers, focusing on colorectal cancer, which is her area of clinical research. Dr. Hubbard is the PI of multiple phase I, II, and III clinical trials investigating novel agents for gastrointestinal cancers. Her research interests also include geriatric oncology with a special interest in clinical and biologic markers of frailty.

    Dr. Hubbard is a member of the National Comprehensive Cancer Network Colon/Rectal/Anal Cancers and Senior Adult Oncology Panels. She serves as a member of the Cancer in the Gastrointestinal Cancers, Older Adult, Health Reported Outcomes, and Translational Research committees for the North American Alliance of Clinical Trials in Oncology Network. She is also a member of the Gastrointestinal Cancer Committee for the Academic and Community Cancer Research United trials network. Dr. Hubbard is program director for the Gastrointestinal Cancer Advanced Fellowship and the Vice-chair for the Division of Medical Oncology at Mayo Clinic in Rochester, MN.

  • Dr. Howard West, M.D.

    Executive Director, AccessHope and Associate Clinical Professor, City of Hope Comprehensive Cancer Center

    Dr. West is an Associate Clinical Professor in Medical Oncology, a specialist in thoracic oncology, and serves as Executive Director of AccessHope remote consult services at City of Hope Comprehensive Cancer Center.

    Dr. West received an MPhil in Experimental Biology from Cambridge University on a Fulbright Scholarship and a medical degree (magna cum laude) from Harvard Medical School, where Dr. West also conducted research as a Howard Hughes Medical Student Fellow. His postdoctoral training included an internship and residency in internal medicine at the Harvard-affiliated Brigham and Women’s Hospital Boston, MA, followed by a fellowship in medical oncology at the Fred Hutchinson Cancer Research Center/University of Washington in Seattle, WA. In late, 2002, he moved to Swedish Cancer Institute in Seattle, where he served for over 16 years as Medical Director of the Thoracic Oncology Program, overseeing a broad array of clinical care and research responsibilities.

    In early 2019, he moved to Los Angeles area to dedicate his focus on innovative approaches to delivering sub-specialist expertise across a broader geography, using tools such as remote case reviews as a clinical leader of the new enterprise from City of Hope, known as AccessHope.

    He has authored dozens of papers and chairs several CME programs and symposia internationally on thoracic oncology, novel educational approaches, and social media in cancer care. In addition to these activities, he is the Founder & President of Global Resource for Advancing Cancer Education (GRACE); Web Editor for JAMA Oncology; regular correspondent for Medscape; and contributing author and section editor in Lung Cancer for UpToDate.

    We are increasingly dependent on technology to move ourselves around and interact with our environment, and we ingest enormous amounts of visual data as part of the process. How we acquire visual data and how we put it to use are tough problems that require innovative solutions. On this panel we discuss the acquisition and analysis of visual data with drone imaging specialist Kespry as well as earth imaging and analytics leaders Orbital Insights and Planet Labs.